Sell 2/11/2025Downgrade
Navco Pharmaceuticals Inc. (NAV.V) was downgraded to E+ from D on 2/11/2025 due to a significant decline in the valuation index, efficiency index and growth index. Net income declined 395.53% from -$129.7 to -$642.7, earnings per share declined from -$0.0023 to -$0.0113, and total capital declined 199.39% from $590.2 to -$586.6.

Sell 12/23/2024Downgrade
Navco Pharmaceuticals Inc. (NAV.V) was downgraded to D from D+ on 12/23/2024 due to a noticeable decline in the total return index and volatility index.

Sell 11/4/2024Upgraded
Navco Pharmaceuticals Inc. (NAV.V) was upgraded to D+ from D on 11/4/2024 due to an increase in the total return index, volatility index and valuation index.

Sell 9/9/2024Upgraded
Navco Pharmaceuticals Inc. (NAV.V) was upgraded to D from E+ on 9/9/2024 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 60.09% from -$288.4 to -$115.1, earnings per share increased from -$0.0055 to -$0.0023, and net income increased 55.9% from -$294.1 to -$129.7.

Sell 9/3/2024Downgrade
Navco Pharmaceuticals Inc. (NAV.V) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index.

Sell 8/16/2024Upgraded
Navco Pharmaceuticals Inc. (NAV.V) was upgraded to D- from E+ on 8/16/2024 due to an increase in the volatility index.

Sell 7/3/2024Downgrade
Navco Pharmaceuticals Inc. (NAV.V) was downgraded to E+ from D- on 7/3/2024 due to a decline in the volatility index and total return index.

Sell 6/14/2024Upgraded
Navco Pharmaceuticals Inc. (NAV.V) was upgraded to D- from E+ on 6/14/2024 due to a noticeable increase in the total return index, volatility index and solvency index.

Sell 1/31/2024Upgraded
Navco Pharmaceuticals Inc. (NAV.V) was upgraded to E+ from E- on 1/31/2024 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0617 to $0.0247.

Sell 9/7/2023None
Navco Pharmaceuticals Inc. (NAV.V) was downgraded to E- from U on 09/07/2023.